Startup profile for Inceptive: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Inceptive funding, valuation and investors

AI-designed mRNA molecules licensed to pharma—founded by Transformer co-author Jakob Uszkoreit.

Keep track of Inceptive

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$100M · September 2024

Latest known valuation

$300M+ (reported)

Series A · September 2024

Total disclosed equity funding

$120M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · Palo Alto, California

Investors in latest funding

Lead: Andreessen Horowitz , NVentures (NVIDIA)

Other: Obvious Ventures

Sources: latest funding Last verified: 2026-07-25

Overview

Inceptive, founded in 2021 in Palo Alto by Jakob Uszkoreit (former Google Brain, Transformer paper co-author), builds AI software that designs mRNA sequences for vaccines and therapeutics—described as "biological software." The platform generates candidate molecules validated in Inceptive labs, then licenses them to pharmaceutical partners for clinical development. A $20M seed preceded a $100M Series A led by Andreessen Horowitz and NVIDIA's NVentures with Obvious Ventures participating, reportedly valuing the company above $300 million. Inceptive disclosed work with a large European pharma on an infectious-disease mRNA vaccine. CBO Kevin Heyries joined from AbCellera in 2024.

Why Inceptive is interesting

Uszkoreit left Google after co-writing "Attention Is All You Need" to apply transformers to RNA design—$100M Series A from a16z and NVentures at $300M+ valuation with unnamed European pharma on a vaccine program.

Product & use cases

Inceptive's AI platform designs novel mRNA sequences optimized for desired biological behavior in target systems, combining generative models with lab validation before out-licensing to drugmakers.

  • Designing mRNA vaccines for infectious diseases with pharma partners
  • Generating RNA therapeutic candidates for licensing rather than full in-house development
  • Horizontal AI capability for the ~310 mRNA programs industry-wide per CEO quote

Key facts

  • Series A (~2024): $100M from a16z and NVentures; total ~$120M raised (Endpoints News)
  • Valuation reported above $300M, ~3x seed (Endpoints/FT)
  • CEO co-authored Transformer paper at Google (CNBC)
  • Partnership with large European pharma on mRNA vaccine (Endpoints News)

Funding history (newest first)

Series A

2024-09 $100M Valuation: $300M+ (reported)

Source: https://endpoints.news/former-google-ai-leader-lands-100m-series-a-raise-for-biological-software-startup/

Seed

2022 $20M

Source: https://endpoints.news/former-google-ai-leader-lands-100m-series-a-raise-for-biological-software-startup/

Investors in our directory

Funds linked from Inceptive's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz

Competitive landscape

Edge: Transformer-architecture pedigree plus NVIDIA compute partnership—platform play licensing to pharma vs. single-asset biotech bet.

Inceptive sits in the AI-for-biologics licensing layer—partnering rather than competing head-on with fully integrated mRNA giants. Uszkoreit's transformer credibility and NVentures compute access differentiate on talent and infrastructure. Proof points depend on partners advancing licensed molecules through clinic.

  • Moderna / BioNTech incumbent

    Integrated mRNA drug developers with internal design capabilities; potential partners or competitors for programs.

  • Generate Biomedicines adjacent

    Generative AI for protein/biologics design; overlapping AI-for-biology thesis different modality focus.

  • DeepMind AlphaFold ecosystem adjacent

    Structure prediction vs. Inceptive's sequence design for RNA behavior.

Notable stories

  • Uszkoreit's self-attention idea at Google became the transformer architecture powering ChatGPT—then he pivoted to RNA (CNBC).
  • NVentures investment includes access to NVIDIA compute platforms beyond equity (FirstWord Pharma).
  • AbCellera veteran Kevin Heyries joined as CBO to lead pharma licensing (Endpoints News).

Industries

Biotech & Life Sciences AI & Machine Learning Healthtech

Related funding articles

Venture Capital Tracker pieces that cover Inceptive's financing or category context.

FAQs about Inceptive

Practical answers founders, operators, and investors typically search for.

Inceptive uses AI to design mRNA molecules, validates them in its labs, and licenses successful candidates to pharmaceutical companies for clinical development.
Jakob Uszkoreit, co-author of the Transformer paper at Google, founded Inceptive in 2021 and serves as CEO.
Andreessen Horowitz (/fund/andreessen-horowitz) led seed and co-led the $100M Series A with NVIDIA's NVentures.
About $120M total—$20M seed plus $100M Series A per Endpoints News and Financial Times reporting.
Uszkoreit's term for AI-designed molecular programs (starting with RNA) intended to behave predictably in biological systems.
Moderna develops and commercializes medicines end-to-end; Inceptive designs molecules and licenses them to partners.
Partners conduct clinical trials on licensed molecules; Inceptive focuses on design and lab validation.
NVentures led part of the Series A; investment includes access to NVIDIA compute for AI training per press reports.
Not publicly disclosed; company is clinical-partnership stage with significant R&D and compute costs.
Reported above $300M at Series A; later social posts cite higher marks—use $300M+ as sourced baseline from Endpoints/FT.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.